178 related articles for article (PubMed ID: 17594934)
1. Severe cutaneous zygomycosis: evaluation of treatment with high doses of liposomal amphotericin B in a one-year old child.
Bandettini R; Tuo P; Tamisani AM; Di Marco E; Mantero E
J Chemother; 2007 Jun; 19(3):347-9. PubMed ID: 17594934
[No Abstract] [Full Text] [Related]
2. Comparison of lipid amphotericin B preparations in treating murine zygomycosis.
Ibrahim AS; Gebremariam T; Husseiny MI; Stevens DA; Fu Y; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2008 Apr; 52(4):1573-6. PubMed ID: 18227182
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.
Crompton JA; Alexander D; Somerville T; Shihab FS
Transpl Infect Dis; 2004 Dec; 6(4):183-7. PubMed ID: 15762937
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of cutaneous zygomycosis.
Visser DH; van den Berg YL; van Furth AM; Oomen MW; Schouten-van Meeteren AY; Pajkrt D; van den Bos C; van Well GT
Pediatr Infect Dis J; 2007 Dec; 26(12):1165-6. PubMed ID: 18043463
[TBL] [Abstract][Full Text] [Related]
6. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection.
Patterson TS; Barton LL; Shehab ZM; Hutter JJ
Clin Pediatr (Phila); 1996 May; 35(5):257-60. PubMed ID: 8804544
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with liposomal amphotericin B of an intraabdomianl abscess due to Candida norvegensis associated with a Gore-Tex mesh infection.
Nolla-Salas J; Torres-RodrÃguez JM; Grau S; Isbert F; Torrella T; Riveiro M; Sitges-Serra A
Scand J Infect Dis; 2000; 32(5):560-2. PubMed ID: 11055666
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of invasive zygomycosis infections in renal transplant recipients.
Forrest GN; Mankes K
Transpl Infect Dis; 2007 Jun; 9(2):161-4. PubMed ID: 17462005
[TBL] [Abstract][Full Text] [Related]
10. Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder.
Castagnola E; Moresco L; Cappelli B; Cuzzubbo D; Moroni C; Lanino E; Faraci M
J Chemother; 2007 Jun; 19(3):339-42. PubMed ID: 17594932
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
Rieg G; Spellberg B; Schwartz J; Fu Y; Edwards JE; Sheppard DC; Ibrahim AS
Antimicrob Agents Chemother; 2006 Aug; 50(8):2895-6. PubMed ID: 16870798
[No Abstract] [Full Text] [Related]
12. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
13. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint H; Kyi AA; Winn RM
J Antimicrob Chemother; 1998 Mar; 41(3):424-6. PubMed ID: 9578177
[No Abstract] [Full Text] [Related]
14. Reversible dilated cardiomyopathy related to amphotericin B therapy.
Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
16. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
17. Intraabdominal zygomycosis caused by Syncephalastrum racemosum infection successfully treated with partial surgical debridement and high-dose amphotericin B lipid complex.
Schlebusch S; Looke DF
J Clin Microbiol; 2005 Nov; 43(11):5825-7. PubMed ID: 16272533
[TBL] [Abstract][Full Text] [Related]
18. Anaphylaxis upon switching lipid-containing amphotericin B formulations.
Kauffman CA; Wiseman SW
Clin Infect Dis; 1998 May; 26(5):1237-8. PubMed ID: 9597266
[No Abstract] [Full Text] [Related]
19. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
